Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2018 09:00 ET | Source: NexImmune, Inc.

NexImmune Management to Attend Upcoming Conferences

GAITHERSBURG, Md., May 30, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the company will be participating in the...
March 27, 2018 07:30 ET | Source: Neximmune, Inc.

NexImmune Announces Management and Board Appointments

Scott Carmer appointed Chief Executive OfficerKristi Jones promoted to Chief Operating OfficerAlan Roemer appointed Chairman of the Board of Directors GAITHERSBURG, Md., March 27, 2018 (GLOBE...
January 02, 2018 07:00 ET | Source: Neximmune, Inc.

NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development

Series A financing co-led by ArrowMark Partners and Barer & Son CapitalFinancing supports initiation of Phase I/II trial of AIMTM ACT in relapsed/refractory Hematologic Malignancies in 2018 ...
October 17, 2017 07:15 ET | Source: Neximmune, Inc.

NexImmune and The Leukemia & Lymphoma Society enter partnership for the development of AIM ACT™ in AML patients

GAITHERSBURG, Md., Oct. 17, 2017 (GLOBE NEWSWIRE) -- NexImmune and The Leukemia & Lymphoma Society (LLS) have entered a partnership to advance the Company’s novel cellular immunotherapy into...
February 14, 2017 07:30 ET | Source: Neximmune, Inc.

NexImmune Acquired by a Consortium of Private Investors Led by Former Celgene and Medtronic CEOs

GAITHERSBURG, Md., Feb. 14, 2017 (GLOBE NEWSWIRE) -- NexImmune, a biopharmaceutical company developing novel immuno-therapeutics based on the Artificial Immune (AIM™) nanotechnology platform, today...

keyboard_arrow_left Previous Page